GlassScriptPhysician profile
Erica L Conley
NPI 1972919165
$15,863.75
in general payments reported to CMS, 2019-2025
42 companies · $3,078 in 2025
The $3,078 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,108 · 2022: $3,510 · 2023: $2,718 · 2024: $3,451 · 2025: $3,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,205 · Education: $41.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,205.17 |
| Education | $41.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $2,280.60 | 2021-2025 | Mounjaro, Jardiance, Humulin |
| Novo Nordisk INC | $2,031.06 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $1,983.00 | 2021-2025 | Minimed 780g, Na, Intellis Adaptivestim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $977.71 | 2021-2025 | Jardiance, Synjardy, Trijardy Xr |
| Abbott Laboratories | $811.24 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $804.69 | 2021-2023 | Farxiga |
| Abbvie INC. | $796.32 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $726.11 | 2021-2025 | |
| Corcept Therapeutics | $627.95 | 2021-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $597.45 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Dexcom, INC. | $543.75 | 2021-2025 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $487.03 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $441.41 | 2021-2025 | Evenity, Repatha, Tepezza |
| Bayer Healthcare Pharmaceuticals INC. | $408.79 | 2021-2025 | |
| Ibsa Pharma INC. | $337.09 | 2021-2025 | Tirosint, Licart, Tirosint |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $258.07 | 2021 | |
| Sequel Med Tech, LLC | $222.80 | 2024-2025 | Twiist |
| Glaxosmithkline, LLC. | $179.68 | 2025 | Arexvy, Shingrix |
| Insulet Corporation | $165.85 | 2021-2025 | Omnipod |
| Pfizer INC. | $138.80 | 2022-2024 | |
| Recordati_rare_diseases_inc. | $128.78 | 2023-2024 | Isturisa, Signifor Lar |
| Merck Sharp & Dohme LLC | $116.65 | 2021 | |
| Esperion Therapeutics, INC. | $97.59 | 2024-2025 | Nexletol |
| Zealand Pharma US, INC. | $93.80 | 2021-2022 | |
| Ascensia Diabetes Care US INC. | $88.55 | 2023 | |
| Neurocrine Biosciences, INC. | $71.21 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $49.93 | 2022 | |
| Becton, Dickinson and Company | $45.97 | 2021-2022 | |
| Boston Scientific Corporation | $44.98 | 2024 | Wavewriter Alpha Prime 16 |
| Chiesi USA, INC. | $44.70 | 2024 | Mycapssa, Myalept |
| Takeda Pharmaceuticals U.S.A., INC. | $32.59 | 2021 | |
| Phathom Pharmaceuticals, INC. | $31.74 | 2024-2025 | Voquezna |
| Grt US Holding, INC. | $29.67 | 2022 | |
| Ionis Pharmaceuticals, INC. | $24.30 | 2025 | Tryngolza |
| Averitas Pharma INC. | $23.85 | 2025 | Qutenza |
| Beta Bionics, INC. | $21.96 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Radius Health, INC. | $18.61 | 2022 | |
| Ascendis Pharma Endocrinology INC | $18.07 | 2025 | Yorvipath |
| Lexicon Pharmaceuticals, INC. | $16.84 | 2023 | Inpefa |
| Kyowa Kirin, INC. | $16.13 | 2024 | Crysvita |
| Tolmar, INC. | $14.87 | 2024 | |
| Soleno Therapeutics, INC. | $13.56 | 2025 | Vykat Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Conley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.